Abelacimab与利伐沙班在房颤合并抗血小板治疗患者中的比较:AZALEA-TIMI 71预设分析
AZALEA-TIMI 71试验的预设分析比较了新型因子XI抑制剂Abelacimab与利伐沙班在房颤患者中的出血风险,按是否联用抗血小板治疗分层。结果显示,无论是否联用抗血小板药物,Abelacimab均显著降低大出血或临床相关非大出血风险,且在联用抗血小板治疗者中绝对风险降低更大。
要点
- Abelacimab 90mg和150mg较利伐沙班显著降低出血风险,联用抗血小板时HR 0.26和0.30。
- 联用抗血小板治疗者中,Abelacimab绝对出血风险降低幅度大于未联用者。
- 因子XI抑制可能为需联用抗血小板治疗的房颤患者提供更安全的抗凝选择。
核心结论
- Abelacimab抑制因子XI可 consistently 降低出血风险,无论是否联用抗血小板治疗,且在联用抗血小板者中绝对风险降低更大。
- 提示因子XI抑制可能为需联用抗血小板治疗的房颤患者提供安全的抗凝选择。
研究设计与样本
- AZALEA-TIMI 71试验的预设分析,随机分配患者至Abelacimab 90mg或150mg皮下每月一次或利伐沙班20mg每日一次(肌酐清除率≤50 mL/min减至15mg)。
- 共纳入1287例患者(44%女性;中位年龄74岁,IQR 69-78),按基线计划联用抗血小板治疗分层,其中318例(24.7%)联用抗血小板治疗。
主要发现
- 联用抗血小板治疗者中,利伐沙班组大出血或临床相关非大出血发生率为10.6/100患者年,无联用者为7.7/100患者年。
- Abelacimab 90mg和150mg联用抗血小板治疗时出血发生率分别为2.5和3.5/100患者年,无联用时为2.7和3.1/100患者年。
- 联用抗血小板治疗者中,Abelacimab 90mg和150mg对比利伐沙班的调整HR分别为0.26(95%CI 0.10-0.70)和0.30(95%CI 0.12-0.74);无联用者分别为0.34(95%CI 0.19-0.60)和0.40(95%CI 0.23-0.68);交互作用P值分别为0.56和0.60。
- 联用抗血小板治疗者中,Abelacimab 90mg和150mg对比利伐沙班的绝对风险降低分别为8.1和7.1,无联用者为5.0和4.6。
临床怎么用
- 对于房颤需联用抗血小板治疗的患者,Abelacimab可能提供比利伐沙班更低的出血风险,尤其适合高出血风险人群。
- 临床决策时需结合患者血栓和出血风险,考虑因子XI抑制剂作为抗凝选择。
局限性
- 本研究为预设亚组分析,联用抗血小板治疗患者样本量有限(318例),结果需进一步验证。
- 研究未报告效能终点,临床硬终点如卒中或栓塞事件的数据需参考主要试验结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Combining antiplatelet therapy (APT) with conventional anticoagulants increases the risk of bleeding. In the AZALEA-TIMI 71 trial (Safety and Tolerability of Abelacimab [MAA868] vs Rivaroxaban in Patients With Atrial Fibrillation), the novel factor XI inhibitor abelacimab significantly reduced the risk of bleeding compared with rivaroxaban in patients with atrial fibrillation. Whether the safety of combination antithrombotic therapy differs in the context of factor XI inhibition has not been well characterized. METHODS: This prespecified analysis of AZALEA-TIMI 71, which randomized patients between March and December of 2021 to 1 of 2 subcutaneous monthly abelacimab doses (90 or 150 mg) or oral rivaroxaban (20 mg daily, dose reduced to 15 mg in patients with creatinine clearance ≤50 mL/min), stratified patients by planned use of concomitant APT. The primary composite end point of major or clinically relevant nonmajor bleeding and other safety and efficacy outcomes were examined by concomitant APT and randomized treatment. RESULTS: Of 1287 patients (44% female; median age 74 years [interquartile range, 69-78]), 318 (24.7%) were on APT at baseline with planned continuation (15.5% aspirin only, 7.5% P2Y12 inhibitor only, and 1.6% dual APT). In the rivaroxaban arm, the rate of major or clinically relevant nonmajor bleeding was 10.6 per 100 patient-years with concomitant APT versus 7.7 per 100 patient-years without. In the abelacimab arms, the rates were 2.5 and 3.5 per 100 patient-years for the 90-mg and 150-mg doses, respectively, with concomitant APT and 2.7 and 3.1 per 100 patient-years without. Each abelacimab dose significantly reduced major or clinically relevant nonmajor bleeding compared with rivaroxaban, both in those with concomitant APT (adjusted hazard ratio, 0.26 [95% CI, 0.10-0.70] and 0.30 [95% CI, 0.12-0.74] for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) and in those without concomitant APT (adjusted hazard ratio, 0.34 [95% CI, 0.19-0.60] and 0.40 [95% CI, 0.23-0.68] for 90 mg and 150 mg of abelacimab, respectively; Pinteractions=0.56 and 0.60, respectively). Patients with concomitant APT tended to derive greater absolute risk reductions with abelacimab (8.1 and 7.1 for 90 mg and 150 mg of abelacimab, respectively, versus rivaroxaban) than those without concomitant APT (5.0 and 4.6, respectively). CONCLUSIONS: Inhibition of factor XI with abelacimab consistently reduced bleeding compared with rivaroxaban regardless of concomitant APT use, with greater absolute reductions in bleeding in those requiring concomitant APT. These data suggest that factor XI inhibition may be a safe anticoagulant option in patients with atrial fibrillation requiring concomitant APT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04755283.
引用
- Al Said, Patel, Giugliano, et al. Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. Circulation. 2025. PMID: 40546068. doi:10.1161/CIRCULATIONAHA.125.074037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。